Dipeptidyl Peptidase IV Inhibitory Activity of Berberine and Mangiferin: An In Silico ApproachJournal: International Journal of Clinical Endocrinology and Metabolism (Vol.3, No. 1)
Publication Date: 2017-12-07
Authors : Ipseeta Ray Mohanty Selvaa Kumar; Rajesh Suman;
Page : 018-022
Keywords : Berberine; Mangiferin; Sitagliptin; Vilda- gliptin; in silico and DPP-IV;
Background: Dipeptidyl peptidase-IV (DDP-IV) Inhibitors may represent single anti-diabetic drugs, the multiple actions of which may translate into demonstrable therapeutic benefits in diabetes. The marketed synthetic DPP-IV Inhibitors are expensive drugs and have been reported to cause unacceptable adverse effects such as pancreatitis, angioedema, thyroid and pancreatic cancers. In this scenario, research to identify DPP-IV Inhibitors from alternative sources is desirable.
Other Latest Articles
Last modified: 2019-01-11 18:04:08